Dr. Martin Markowitz is a graduate of Stanford Medical School and completed his postgraduate training in Hematology/Oncology at Cornell Medical College and Infectious Diseases at New York University.
Dr. Markowitz has worked at the Aaron Diamond AIDS Research Center (ADARC) since 1992 and currently holds the positions of Clinical Director and Staff Investigator at ADARC and is an Aaron Diamond Professor at the Rockefeller University. His seminal work in elucidating the dynamics of HIV-1 infection in vivo along with his mentor Dr. David Ho and colleagues at the Aaron Diamond AIDS Research Center formed the scientific foundation for triple combination therapy, a treatment paradigm that to this day remains the current standard of care. In addition, his research interests have included the pathogenesis and treatment of acute HIV-1 infection, the fitness and transmission of drug resistant HIV-1, and investigations of numerous novel antiretroviral agents as well as pathogenesis-based interventional trials. His group at the Aaron Diamond have performed pivotal preclinical studies testing the efficacy of Cabotegravir-Long Acting (CAB-LA) as PrEP in the rhesus macaque/SHIV162P3 non-human primate model of mucosal transmission. He is the Principal Investigator of “A Phase IIa Study to Evaluate the Safety, Tolerability and Acceptability of Long Acting Injections of the HIV Integrase Inhibitor, Cabotegravir, in HIV Uninfected Men (ÉCLAIR)”. He is the Chair of the Protocol Working Group charged with developing a multinational Phase IIb efficacy study of CAB-LA in high-risk men who have sex with men.
